Propranolol

Introduction Overview

Generic Name

propranolol

Brand Name

Hemangeol, Inderal LA, Inderal XL, InnoPran XL, Inderal, Propranolol Hydrochloride ER

Dosage Form

intravenous solution (1 mg/mL), oral capsule extended release (60 mg, 80 mg, 120 mg, 160 mg), oral liquid (4.28 mg/mL), oral solution (20 mg/5 mL; 40 mg/5 mL), oral tablet (10 mg, 20 mg, 40 mg, 60 mg, 80 mg)

Drug Class

Group II antiarrhythmics, Non-cardioselective beta blockers

Pharmacokinetics

Absorption: Propranolol is rapidly and well absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations of immediate-release formulations typically occur within 1 to 4 hours post-dose, whereas extended-release forms reach peak plasma levels roughly 6 hours after administration. Oral bioavailability is variable and ranges from 25% to 35%, primarily due to extensive first-pass hepatic metabolism. Food intake does not significantly alter the extent of propranolol absorption but may delay the time to peak levels. The lipophilic nature of propranolol facilitates its absorption but also subjects it to significant presystemic metabolism, resulting in marked interindividual variability.

Distribution: Propranolol exhibits widespread distribution throughout the body, readily crossing cell membranes due to its high lipophilicity. It binds extensively to plasma proteins, predominantly albumin, with an approximate binding rate of 90%. Its volume of distribution is large, commonly cited between 3 to 5 L/kg, indicating extensive tissue penetration including the heart, lungs, liver, kidneys, and central nervous system. The ability to cross the blood-brain barrier is relevant for its central nervous system effects. Accumulation in tissues has clinical implications for both therapeutic actions and side effects.

Metabolism: Propranolol undergoes almost complete hepatic metabolism involving oxidative pathways primarily by cytochrome P450 enzymes, especially CYP2D6 and CYP1A2. The metabolic process includes hydroxylation, conjugation with glucuronic acid, and other modifications leading to multiple metabolites, which have negligible beta-blocking activity. Genetic polymorphisms of CYP2D6 can impact plasma levels and clinical response. Extensive first-pass metabolism significantly reduces its systemic availability. Pathological conditions affecting liver function or concurrent medications modifying CYP enzyme activity can greatly influence propranolol metabolism.

Elimination: The elimination half-life of propranolol ranges from 3 to 6 hours for immediate-release formulations, whereas extended-release preparations allow longer duration of action by sustaining plasma concentrations. Excretion occurs mainly via renal routes following hepatic metabolism, with less than 1% excreted unchanged in urine. The drug is cleared through both metabolism and biliary excretion. Renal impairment has limited impact on propranolol elimination because of the hepatic predominance, but severe liver disease can prolong its half-life. Approximately five half-lives, or 15 to 30 hours, are required for complete clearance from the body. Therapeutic monitoring is generally not required but may be considered in patients with hepatic dysfunction or concomitant drug use affecting hepatic enzymes.

Dosage Forms

Available Dosage Forms:
- Intravenous solution: 1 mg/mL
- Oral capsule extended release: 60 mg, 80 mg, 120 mg, 160 mg
- Oral liquid (Hemangeol): 4.28 mg/mL
- Oral solution: 20 mg/5 mL, 40 mg/5 mL
- Oral tablet: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg

Dosages for Adults and Adolescents:
For hypertension, angina pectoris, and arrhythmias, oral propranolol immediate-release tablets generally start at 40 mg twice daily, adjusted gradually to a maintenance dose ranging from 80 mg to 320 mg per day, divided into two or three doses. Extended-release capsules are typically started at 80 mg once daily and may be titrated up to 160 mg or 240 mg once daily depending on clinical response. For migraine prophylaxis, doses often range from 80 mg to 240 mg daily. Intravenous administration is reserved for acute management of arrhythmias and hypertensive emergencies, with doses administered carefully under monitoring.

In pediatric patients, Hemangeol oral liquid is approved for infantile hemangiomas in infants aged 5 weeks to 1 year, with dosing based on weight, often starting at 1.0 mg/kg/day divided every 8 to 12 hours. Close monitoring for hypoglycemia and bradycardia is critical. Dosage adjustments must account for weight changes.

Specific Patient Populations:
- Infants: Use Hemangeol oral liquid for infantile hemangioma with weight-based dosing; contraindicated in infants less than 4.4 pounds (approximately 2 kg).
- Elderly: Initiate therapy at lower doses due to potential for increased sensitivity and comorbidities.
- Hepatic impairment: Dose adjustments may be necessary because of reduced metabolism and clearance.
- Renal impairment: Generally, no adjustment is required, but monitoring is prudent.
- Patients with asthma, severe bradycardia, sick sinus syndrome, or high-degree AV block should avoid propranolol or use only with a pacemaker under specialist supervision.

Mechanism Of Action

Propranolol is a non-selective beta-adrenergic receptor antagonist that blocks both beta-1 and beta-2 adrenergic receptors, thereby inhibiting the effects of endogenous catecholamines such as norepinephrine and epinephrine. By blocking beta-1 receptors predominantly located in cardiac tissue, propranolol decreases the heart rate (negative chronotropic effect), reduces myocardial contractility (negative inotropic effect), and diminishes cardiac output, contributing to its therapeutic efficacy in managing hypertension, angina, and arrhythmias.

At the molecular level, propranolol competitively inhibits the binding of catecholamines to beta-adrenergic receptors on cardiac myocytes and conduction tissue, thereby reducing cyclic AMP (cAMP) levels and subsequent activation of protein kinase A (PKA). This leads to decreased phosphorylation of calcium channels and reduced intracellular calcium influx, which translates to diminished cardiac contractile force and conduction velocity.

Propranolol’s blockade of beta-2 adrenergic receptors, which are present in bronchial and vascular smooth muscle, results in bronchoconstriction and vasoconstriction, respectively, accounting for some of its contraindications in asthma and peripheral vascular disease. It also reduces renin release from the juxtaglomerular cells in the kidney, lowering plasma renin activity and contributing to blood pressure-lowering effects.

Clinically, propranolol’s ability to cross the blood-brain barrier due to its lipophilic nature imparts central nervous system effects such as suppression of sympathetic outflow, which underlies its use in migraine prophylaxis and anxiety-related conditions like performance anxiety. Compared to cardio-selective beta blockers, propranolol’s broader receptor profile results in a wider range of therapeutic and side effects. Extensive clinical studies validate propranolol’s efficacy in a spectrum of cardiovascular and non-cardiovascular indications, with its mechanism well characterized in molecular pharmacology and cardiac electrophysiology research.

Pharmacological Actions

Non-selective beta-adrenergic receptor blockade (beta-1 and beta-2 receptors)
Reduction of heart rate (negative chronotropic effect)
Decrease in myocardial contractility (negative inotropic effect)
Suppression of cardiac conduction velocity (negative dromotropic effect)
Reduction of myocardial oxygen demand via decreased cardiac workload
Inhibition of renin release from renal juxtaglomerular cells lowering plasma renin activity
Bronchoconstriction due to beta-2 receptor antagonism in pulmonary smooth muscle
Vasoconstriction in peripheral blood vessels via beta-2 receptor blockade
Central nervous system beta-blockade leading to sedation and anti-anxiety effects
Stabilization of cardiac arrhythmias through anti-arrhythmic properties (Group II antiarrhythmic)
Prophylactic reduction in frequency and severity of migraine headaches
Inhibition of tremor through CNS beta-blockade
Attenuation of hyperadrenergic states including pheochromocytoma-associated symptoms
Reduction of portal hypertension in select patients

Therapeutic Or Clinical Uses

Management of hypertension (high blood pressure)
Treatment of angina pectoris (chest pain) to reduce myocardial ischemia
Control of cardiac arrhythmias including atrial fibrillation and ventricular tachycardia
Secondary prevention after myocardial infarction (heart attack)
Prophylaxis and treatment of migraine headaches
Treatment of essential tremor to reduce shaking
Management of infantile hemangiomas in infants (using Hemangeol oral liquid)
Reduction of symptoms associated with pheochromocytoma (used with alpha-blockers)
Off-label use in the management of performance anxiety and social anxiety symptoms
Prevention of sudden cardiac death in patients with certain cardiac conditions
Treatment of hypertrophic cardiomyopathy symptoms
Management of akathisia and certain movement disorders as adjunct therapy
Control of symptoms in portal hypertension-related variceal bleeding
Reduction of thyroid storm manifestations via adrenergic blockade
Management of postural tachycardia syndrome (POTS) in certain cases

Side Or Adverse Effects

Bradycardia and heart block potentially causing dizziness or syncope
Hypotension possibly manifesting as light-headedness or fainting
Fatigue, lethargy, and somnolence due to central nervous system effects
Bronchospasm or exacerbation of asthma symptoms from beta-2 blockade
Gastrointestinal disturbances including nausea, vomiting, diarrhea, and constipation
Sleep disturbances such as insomnia and vivid dreams
Cold extremities and Raynaud's phenomenon due to peripheral vasoconstriction
Depression, confusion, and hallucinations associated with CNS penetration
Hypoglycemia and masking of hypoglycemia symptoms, which is critical in diabetics
Sexual dysfunction including decreased libido and erectile dysfunction
Weight gain with prolonged therapy in some patients
Exacerbation of heart failure symptoms in susceptible individuals
Allergic reactions including rash, urticaria, and rare severe skin reactions
Worsening of peripheral vascular disease symptoms
Withdrawal syndrome characterized by angina, myocardial infarction, or arrhythmias on abrupt cessation

Precautions

Use caution in patients with reactive airway diseases such as asthma or COPD
Monitor heart rate and blood pressure regularly to prevent symptomatic bradycardia and hypotension
Adjust dose cautiously in patients with heart failure, starting at low doses
Beware of hypoglycemia in diabetic patients and monitor blood glucose closely
Gradually taper propranolol dose to avoid withdrawal effects, especially in ischemic heart disease
Use with caution in patients with peripheral vascular disease or Raynaud's syndrome
Assess renal and hepatic function prior to initiation and periodically during therapy
Scrutinize medication history for potential drug interactions that affect metabolism and efficacy
Exercise caution during pregnancy and breastfeeding; assess risk-benefit ratio thoroughly
Patients should be informed about the possible CNS side effects such as fatigue and depression
Avoid abrupt discontinuation prior to surgery without medical guidance
Consider potential masking of hyperthyroidism symptoms leading to delayed diagnosis
Be alert for signs of worsening heart block, especially in patients without pacemakers
Inform patients about possible sexual side effects and counsel appropriately
Regularly evaluate for signs of fluid retention or worsening congestive heart failure

Warnings

Contraindicated in patients with asthma or reactive airway disease due to risk of bronchospasm
Not to be used in severe bradycardia, sick sinus syndrome, or second- or third-degree AV block unless a pacemaker is present
Should not be given to infants weighing less than 4.4 pounds (approx. 2 kg) when using Hemangeol oral liquid
Use caution in patients with severe heart failure requiring hospitalization
Abrupt withdrawal can precipitate severe exacerbation of angina, myocardial infarction, or ventricular arrhythmias
Caution in patients with uncontrolled diabetes mellitus due to potential masking of hypoglycemia symptoms
Risk of hypotension and syncope particularly in volume-depleted patients
Can exacerbate symptoms of peripheral vascular disease such as Raynaud's phenomenon
Potential CNS adverse reactions including depression and hallucinations may occur
Avoid use in patients with pheochromocytoma unless alpha-blockade is established
May obscure signs of thyrotoxicosis leading to delayed diagnosis
Use in patients undergoing anesthesia may cause additive cardiovascular effects
Avoid alcohol consumption as it may increase propranolol plasma concentrations and effects
Pregnancy and lactation use requires medical supervision due to possible fetal/neonatal risks
Patients should be monitored for signs of severe allergic skin reactions

Contraindication

Known hypersensitivity or allergy to propranolol or any beta-blocker
Asthma or any history of bronchospastic reactive airway disease
Second- or third-degree atrioventricular (AV) block without a pacemaker
Sick sinus syndrome without pacemaker
Severe bradycardia (heart rate below 45 beats per minute)
Severe congestive heart failure requiring hospitalization
Cardiogenic shock or heart block (unless a functioning pacemaker is present)
Infants weighing less than 4.4 pounds (approximately 2 kg) for Hemangeol use
Patients with untreated pheochromocytoma prior to adequate alpha-blockade
Severe peripheral arterial circulatory disorders where beta-blockade could worsen symptoms

Drug Interactions

Cholestyramine and colestipol can decrease absorption of propranolol
Warfarin dosage and effects may be altered by propranolol leading to increased bleeding risk
Antidepressants such as fluoxetine can inhibit propranolol metabolism increasing toxicity
Other antihypertensive agents may have additive effects with propranolol causing hypotension
Nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin, ibuprofen, naproxen, and celecoxib can reduce antihypertensive effect of propranolol
Steroid medications may interact altering blood pressure control
Drugs used to treat infections like rifampin can induce metabolism reducing propranolol levels
Prostate disorder medications such as alpha-blockers may have additive hypotensive effects
Calcium channel blockers (e.g., verapamil, diltiazem) may potentiate cardiac depression when combined
Hypoglycemic agents’ effects can be masked by propranolol, complicating diabetes management
Antiarrhythmic drugs combined with propranolol may increase risk of bradycardia or heart block
CYP2D6 inhibitors can raise plasma levels of propranolol increasing adverse effects
Alcohol may increase plasma concentrations leading to enhanced side effects
Concurrent use with anesthetics may augment cardiac depression
Beta-agonists like albuterol may have reduced efficacy when combined with propranolol

Preparations Of The Drug

Propranolol hydrochloride intravenous solution at 1 mg/mL for acute inpatient use
Extended-release oral capsules in dosages of 60 mg, 80 mg, 120 mg, and 160 mg for once-daily administration
Oral liquid formulation (Hemangeol) at 4.28 mg/mL specifically for infantile hemangiomas
Oral solution available at concentrations of 20 mg/5 mL and 40 mg/5 mL for flexible dosing
Immediate-release oral tablets in doses of 10 mg, 20 mg, 40 mg, 60 mg, and 80 mg for multiple daily dosing
Combination therapy products are not available; propranolol is typically administered as monotherapy
Commercial packaging includes measuring devices for oral liquids to ensure accurate pediatric dosing
Formulations vary in release kinetics to accommodate different therapeutic needs including sustained effect
Commercially available under multiple brand names including Inderal, InnoPran XL, and Hemangeol
Non-prescription forms are unavailable; propranolol requires medical prescription and monitoring